Talphera, Inc. (TLPH) — SEC Filings
Talphera, Inc. (TLPH) — 30 SEC filings. Latest: EFFECT (Apr 2, 2026). Includes 15 8-K, 6 10-Q, 2 DEF 14A.
View Talphera, Inc. on SEC EDGAR
Overview
Talphera, Inc. (TLPH) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a EFFECT filed on Apr 2, 2026: Talphera, Inc. filed an EFFECT form with the SEC on April 2, 2026, indicating the effectiveness of a registration statement. The effectiveness date is April 1, 2026, related to file number 333-294580.
Sentiment Summary
Across 30 filings, the sentiment breakdown is: 6 bearish, 22 neutral, 2 mixed. The dominant filing sentiment for Talphera, Inc. is neutral.
Filing Type Overview
Talphera, Inc. (TLPH) has filed 1 EFFECT, 6 10-Q, 15 8-K, 2 DEF 14A, 1 10-K/A, 2 10-K, 2 SC 13G/A, 1 SC 13D with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (30)
Risk Profile
Risk Assessment: Of TLPH's 24 recent filings, 6 were flagged as high-risk, 11 as medium-risk, and 7 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $1,000 |
| Net Income | -$4.436M |
| EPS | N/A |
| Debt-to-Equity | 0.60 |
| Cash Position | $3.457M |
| Operating Margin | -99.9% |
| Total Assets | $30.742M |
| Total Debt | $11.565M |
Key Executives
- Jonathan M. J. Lim
- David J. E. J. Van Den Berg
- Adrian Adams
- Dr. David J. Bearss
- Jonathan F. Miller
- Sarah E. Empey
Industry Context
Talphera operates in the biotechnology or pharmaceutical sector, characterized by high R&D costs, long development cycles, and significant regulatory hurdles. The industry is highly competitive, with companies vying for market share through innovation and clinical trial success. Recent trends include increased focus on specialized therapies and the impact of evolving healthcare policies on drug pricing and market access.
Top Tags
corporate-action (6) · material-agreement (5) · financials (4) · 10-Q (4) · Pharmaceuticals (3) · corporate-governance (3) · equity-sale (3) · delisting (3) · pharmaceuticals (3) · Biotechnology (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| File Number | 333-294580 | Related to the registration statement |
| Net loss for Q3 2025 | $4.436M | Increased from $3.353M in Q3 2024 |
| Net loss for nine months ended Sep 30, 2025 | $10.518M | Improved from $11.134M in the prior year period |
| Cash and cash equivalents as of Sep 30, 2025 | $3.457M | Decreased from $8.863M at Dec 31, 2024 |
| Net proceeds from equity financing | $21.333M | Raised during the nine months ended Sep 30, 2025 |
| Loss on change in fair value of warrant liability | $1.095M | Contributed to increased Q3 2025 net loss |
| Revenue for Q3 2025 | $1,000 | Up from zero in Q3 2024 |
| Revenue for nine months ended Sep 30, 2025 | $28,000 | Up from zero in the prior year period |
| Research and development expenses for Q3 2025 | $1.803M | Decreased from $2.053M in Q3 2024 |
| Selling, general and administrative expenses for Q3 2025 | $1.620M | Decreased from $1.696M in Q3 2024 |
| Outstanding shares of common stock | 46,609,618 | As of November 5, 2025 |
| Commission File Number | 001-35068 | Identifies the company's SEC filing record. |
| IRS Employer Identification No. | 41-2193603 | Company's tax identification number. |
| SEC File Number | 001-35068 | Identifies the company's filing history with the SEC. |
| Shares of common stock outstanding | 20,522,655 | Entitled to vote as of August 29, 2025 record date |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Talphera, Inc. (TLPH)?
Talphera, Inc. has 30 recent SEC filings from Jan 2024 to Apr 2026, including 15 8-K, 6 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of TLPH filings?
Across 30 filings, the sentiment breakdown is: 6 bearish, 22 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Talphera, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Talphera, Inc. (TLPH) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Talphera, Inc.?
Key financial highlights from Talphera, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for TLPH?
The investment thesis for TLPH includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Talphera, Inc.?
Key executives identified across Talphera, Inc.'s filings include Jonathan M. J. Lim, David J. E. J. Van Den Berg, Adrian Adams, Dr. David J. Bearss, Jonathan F. Miller and 1 others.
What are the main risk factors for Talphera, Inc. stock?
Of TLPH's 24 assessed filings, 6 were flagged high-risk, 11 medium-risk, and 7 low-risk.
What are recent predictions and forward guidance from Talphera, Inc.?
Forward guidance and predictions for Talphera, Inc. are extracted from SEC filings as they are enriched.